Prion Disease Induces Alzheimer Disease-Like Neuropathologic Changes

Journal of Neuropathology and Experimental Neurology

Volumn 74, Issue 9, 2015, Pages 873-888

  Tousseyn, Thomas ^a   Bajsarowicz, Krystyna ^a   Sánchez, Henry ^a   Gheyara, Ania ^a   Oehler, Abby ^a   Geschwind, Michael ^a   DeArmond, Bernadette ^a   DeArmond, Stephen J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer disease; A 42; Codon 129; Creutzfeldt Jakob disease; Female to male ratio; PrPSc; Tau hyperphosphorylation

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; PRION PROTEIN; PROTEIN AGGREGATE; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN HOMOGENATE; BRAIN LEVEL; CELL INCLUSION; CELL LOSS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FETUS; HIPPOCAMPAL CA1 REGION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NEUROPATHOLOGY; NEUROPIL THREAD; NONHUMAN; PERIKARYON; PRION DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCRAPIE; SPORADIC CREUTZFELDT JAKOB DISEASE; VERY ELDERLY; WESTERN BLOTTING; ANIMAL; BRAIN; GENETICS; PATHOLOGY; TRANSGENIC MOUSE;

AGED; ALZHEIMER DISEASE; ANIMALS; BRAIN; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; PRION DISEASES;

EID: 84940537358     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000228     Document Type: Article

References (47)

1. Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, Budka H. Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol 1998;96:116-22
2. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009;457:1128-32
3. Parkin ET, Watt NT, Hussain I, et al. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci U S A 2007;104:11062-67
4. Kovacs GG, Seguin J, Quadrio I, et al. Genetic Creutzfeldt-Jakob disease associated with the E220K mutation: Characterization of a complex proteinopathy. Acta Neuropathol 2011;121:39-57
5. Thal DR, Rüb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-800
6. Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship. J Neuropathol Exp Neurol 2009;68:1-14
7. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011;70:960-69
8. Boyle PA, Yu L, Wilson RS, Schneider JA, Bennett DA. Relation of neuropathology with cognitive decline among older persons without dementia. Front Aging Neurosci 2013;5:50
9. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol 2012;71:362-81
10. Bajsarowicz K, Ahn M, Ackerman L, Dearmond BN, Carlson G, DeArmond SJ. A brain aggregate model gives new insights into the pathobiology and treatment of prion diseases. J Neuropathol Exp Neurol 2012;71:449-66
11. Taraboulos A, Jendroska K, Serban D, Yang SL, DeArmond SJ, Prusiner SB. Regional mapping of prion proteins in brain. Proc Natl Acad Sci U S A 1992;89:7620-24
12. DeArmond SJ, Yang S-L, Lee A, et al. Three scrapie prion isolates exhibit different accumulation patterns of the prion protein scrapie isoform. Proc Natl Acad Sci U S A 1993;90:6449-53
13. Jendroska K, Poewe W, Daniel SE, et al. Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol 1995;90:461-66
14. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41:479-86
15. Ramsden M, Kotilinek L, Forster C, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 2005;25:10637-47
16. Westerman MA, Cooper-Blacketer D, Mariash A, et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2002;22:1858-67
17. Mirra SS, Hart MN, Terry RD. Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. Arch Pathol Lab Med 1993; 117:132-44
18. Rocca WA, Amaducci LA, Schoenberg BS. Epidemiology of clinically diagnosed Alzheimer's disease. Ann Neurol 1986;19:415-24
19. Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: A meta-analysis. Arch Gen Psychiatry 1998;55:809-15
20. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-23
21. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7:180-84
22. Martinez M, Campion D, Brice A, et al. Apolipoprotein E epsilon4 allele and familial aggregation of Alzheimer disease. Arch Neurol 1998;55:810-16
23. Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene of the ApoE locus. J Neurosci 2006;26:4985-94
24. Hashimoto Y, Jiang H, Niikura T, et al. Neuronal apoptosis by apolipoprotein E4 through low-density lipoprotein receptorYrelated protein and heterotrimeric GTPases. J Neurosci 2000;20:8401-9
25. Holman RC, Khan AS, Belay ED, Schonberger LB. Creutzfeldt-Jakob disease in the United States, 1979-1994: Using national mortality data to assess the possible occurrence of variant cases. Emerg Infect Dis 1996;2:333-37
26. Rocca WA, Petersen RC, Knopman DS, et al. Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement 2011;7:80-93
27. Mar J, Soto-Gordoa M, Arrospide A, Moreno-Izco F, Martínez-Lage P. Fitting the epidemiology and neuropathology of the early stages of Alzheimer's disease to prevent dementia. Alzheimers Res Ther 2015;7:2
28. Reiniger L, Lukic A, Linehan J, et al. Tau, prions and AA: The triad of neurodegeneration. Acta Neuropathol 2011;121:5-20
29. Umeda T, Tomiyama T, Sakama N, et al. Intraneuronal amyloid A oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci 2011;89:1031-42
30. Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression: Beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol 1994; 53:429-37
31. Tai LM, Mehra S, Shete V, et al. Soluble apoE/AA complex: Mechanism and therapeutic target for APOE4-induced AD risk. Mol Neurodegener 2014;9:2
32. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72
33. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-56
34. Shirotani K, Tsubuki S, Iwata N, et al. Neprilysin degrades both amyloid A peptides 1-40 and 1-42 most rapidly and efficiently among thiorphanand phosphoramidon-sensitive endopeptidases. J Biol Chem 2001;276: 21895-901
35. Grimm MO, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T. Neprilysin and AA clearance: Impact of the APP intracellular domain in NEP regulation and implications in Alzheimer's disease. Front Aging Neurosci 2013;5:98
36. Blacker D, Haines JL, Rodes L, et al. ApoE-4 and age at onset of Alzheimer's disease: The NIMH genetics initiative. Neurology 1997;48:139-47
37. Chapman J, Cervenakova L, Petersen RB, et al. APOE in non-Alzheimer amyloidoses: Transmissible spongiform encephalopathies. Neurology 1998;51:548-53
38. Palmer MS, Dryden AJ, Hughes JT, Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 1991;352:340-42
39. Collinge J, Sidle K, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996;383:685-90
40. Brown P, Will RG, Bradley R, Asher DM, Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: Background, evolution, and current concerns. Emerg Infect Dis 2001;7:6-16
41. Riemenschneider M, Klopp N, Xiang W, et al. Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology 2004;63: 364-66
42. Dermaut B, Croes EA, Rademakers R, et al. PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease. Ann Neurol 2003;53:409-12
43. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256-61
44. Hebert LE, Scherr PA, McCann JJ, Beckett LA, Evans DA. Is the risk of developing Alzheimer's disease greater for women than for men? Am J Epidemiol 2001;153:132-36
45. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002;58: 192-97
46. Skillbäck T, Rosén C, Asztely F, Mattsson N, Blennow K, Zetterberg H. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: Results from the Swedish Mortality Registry. JAMA Neurol 2014;71:476-83
47. Wang G-R, Gao C, Shi Q, et al. Elevated levels of tau protein in cerebrospinal fluid of patients with probable Creutzfeldt-Jakob disease. Am J Med Sci 2010;340:291-95